about
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death.A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England.Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK.The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results.The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016.A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.The cost-effectiveness of seven behavioural interventions to prevent drug misuse in vulnerable populations.Smoking Cessation: A Comparison of Two Model StructuresLubiprostone In Chronic Idiopathic Constipation: A Cost-Effectiveness AnalysisWhich Metric To Choose For Indirect Comparison Of Treatments When Multiple Comparisons Are Feasible: Lubiprostone Verse Prucalopride In Chronic ConstipationMRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy studyThe Impact of Moving from EQ-5D-3L to -5L in NICE Technology AppraisalsEvaluation of Intervention Impact on Health Inequality for Resource AllocationDinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal
P50
Q34235050-23E6ACB1-15A1-4F87-9514-1EC24D97AB38Q39415996-7323B278-9989-4E82-8B46-1AF96BFC804AQ40975772-55D945A5-72CE-46AE-9504-1A65AE200D92Q47179802-256DD807-039C-4E3E-A7A3-3A34107991A9Q48056504-F0A6554C-BA33-4AEB-8E9C-80ECAF4DD94AQ49607011-7589E310-5851-4CB9-8D4B-A8F6D766707BQ50671434-BB3CFF64-52B1-4267-BDE3-43DBACF1E16BQ54231087-6A3EC5A8-1D2A-4D09-9637-D01C067654F7Q88599535-987FB4D5-995C-42C6-862A-96C1747E7239Q89239327-B45EBFC6-89D6-4E15-B684-821362D5E4F2Q89239395-D65352D6-2AF8-4A13-A6EA-E7D1DC1A4F2DQ90186794-5F4715E1-887C-4918-A387-D013D243DDFEQ90864708-D6249C3A-5A67-4751-8CC4-84A9F4DD5EBCQ92016652-5A5DC662-6AD2-4712-A27B-B2529676AE80Q93346111-B376C23A-9E07-4D8A-A290-9865FEB24E54
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1002-022X
@en
name
B Pennington
@ast
B Pennington
@nl
Becky Pennington
@en
Becky Pennington
@pl
type
label
B Pennington
@ast
B Pennington
@nl
Becky Pennington
@en
Becky Pennington
@pl
altLabel
B Pennington
@en
prefLabel
B Pennington
@ast
B Pennington
@nl
Becky Pennington
@en
Becky Pennington
@pl
P106
P31
P496
0000-0002-1002-022X